Product Images Fluticasone Propionate And Salmeterol Diskus
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 16 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 50090-4211 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
fluticasone propionate chemical structure - fp sal spl graphic 01
salmeterol xinafoate chemical structure - fp sal spl graphic 02
Figure 1. Mean Percent Change From Baseline in FEV1 in Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
The text seems to be a table that shows the effects of different medication dosages on FEV (forced expiratory volume). The table includes columns with drug names, doses, week number, and change in FEV. However, since there are missing values and unclear formatting, it is difficult to give an accurate description.*
Figure 2. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
This appears to be a graph showcasing the change in FEV4 (a measure of lung function) over time for four different treatment groups. The groups include a combination treatment of Fluticasone propionate and salmeterol, salmeterol alone, Fluticasone propionate alone, and a placebo. The graph shows a 9% change in FEV4 for the combination treatment group, and baseline values are also shown for all groups.*
Figure 3. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
This appears to be a graph or chart displaying changes in FEV (forced expiratory volume) relative to a baseline measurement on different medication treatments. It includes data for Fluticasone propionate/salmeterol, Salmeterol, Fluticasone propionate, and a Placebo group. The chart seems to be tracking changes over the course of 12 weeks.*
Figure 4. Predose FEV1: Mean Percent Change From Baseline in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
This appears to be a graph showing a comparison of the effects of three different treatments on lung function (FEV) over a period of 24 weeks. The first treatment involves a combination of fluticasone propionate and salmeterol taken twice daily, the second treatment involves only salmeterol taken twice daily, and the third treatment is a placebo. The graph shows that both the treatments involving medication resulted in improved lung function compared to the placebo group.*
Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes From Baseline Over Time in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
This is a table showing the results of a study comparing the effects of Fluticasone Propionate/Salmeterol 250/50 mcg twice a day, Fluticasone Propionate 250 mcg twice a day, and Placebo on baseline FEV. The results are presented in the form of a chart with different endpoints, and the number of participants with various measurements at each endpoint is presented for each group.*
Figure A - fp sal spl graphic 08
Figure B - fp sal spl graphic 09
Figure C - fp sal spl graphic 10
IFU Figure D - fp sal spl graphic 11
Figure E - fp sal spl graphic 12
Figure F - fp sal spl graphic 13
IFU Figure G - fp sal spl graphic 14
Figure H - fp sal spl graphic 15
Label Image - lbl500904211
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.